Tumor cells incapable of using ketone bodies can still grow in vivo if highly glycolytic

There has been increasing interest in the potential efficacy of a ketogenic diet in the treatment of cancer. One of the proposed rationales for this is that cancer cells, unlike normal cells, lack the ketolytic enzymes required to utilize ketone bodies for energy, causing selective death to cancer cells under low glucose conditions. In this study, we asked whether cancer cells uniformly lack ketolytic enzymes and whether this correlated with their ability to utilize ketone bodies for survival under low-glucose conditions. In addition, we determined if these in vitro assays could predict the efficacy of a ketogenic diet in vivo using preclinical mouse models. We screened multiple cancer cell lines for their expression of 3-oxoacid CoA-transferase 1 (OXCT1) and β-hydroxybutyrate dehydrogenase (BDH1), and evaluated their survival under β-hydroxybutyrate (βHB)-supplemented glucose free conditions. We also determined the extent by which βHB is depleted in the cell culture media. The expression of OXCT1 and BDH1 varies between cancer cell lines, and did not always correspond to functional ketone utilization. Furthermore, when tested in vivo using tumor-implanted mouse models, many cancer cells grew regardless of their predicted ketolytic capacity, highlighting the limited ability of these in vitro findings to predict in vivo efficacy. The growth of SW480 colon cancer cells, shown in vitro to be a user of βHB, was slowed to a greater extent when implanted in vivo to mice fed a ketogenic diet, when compared to H1299 lung cancer cells, which were not a user of βHB in vitro. Further investigations suggest that H1299 is a greater producer of lactate, which we hypothesize is being converted back to glucose in the liver via gluconeogenesis, causing the observed higher blood glucose and plasma insulin. This in turn, supports the growth of the H1299 cells in vivo, that could not be predicted by our in vitro assays. Taken together, we show that while it is not possible to predict the efficacy of a ketogenic diet using in vitro assays, it may be possible to identify which cancer cells may be impacted under low glucose conditions based on its propensity to produce lactate via glycolysis.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-11-16
DOI
https://doi.org/10.1371/journal.pone.0362670
Primary Topic
Diet and metabolism studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Tumor cells incapable of using ketone bodies can still grow in vivo if highly glycolytic

Ingrid Elisia, Nicola Janz, Gerald Krystal, Michelle Yeung et al.
1 links
PLoS ONE
Diet and metabolism studies
article

Tumor cells incapable of using ketone bodies can still grow in vivo if highly glycolytic

Ingrid Elisia, Nicola Janz, Gerald Krystal, Michelle Yeung, Vianne Chang, Michaela Schweitzer, Xunfei Mao
article en

Abstract

There has been increasing interest in the potential efficacy of a ketogenic diet in the treatment of cancer. One of the proposed rationales for this is that cancer cells, unlike normal cells, lack the ketolytic enzymes required to utilize ketone bodies for energy, causing selective death to cancer cells under low glucose conditions. In this study, we asked whether cancer cells uniformly lack ketolytic enzymes and whether this correlated with their ability to utilize ketone bodies for survival under low-glucose conditions. In addition, we determined if these in vitro assays could predict the efficacy of a ketogenic diet in vivo using preclinical mouse models. We screened multiple cancer cell lines for their expression of 3-oxoacid CoA-transferase 1 (OXCT1) and β-hydroxybutyrate dehydrogenase (BDH1), and evaluated their survival under β-hydroxybutyrate (βHB)-supplemented glucose free conditions. We also determined the extent by which βHB is depleted in the cell culture media. The expression of OXCT1 and BDH1 varies between cancer cell lines, and did not always correspond to functional ketone utilization. Furthermore, when tested in vivo using tumor-implanted mouse models, many cancer cells grew regardless of their predicted ketolytic capacity, highlighting the limited ability of these in vitro findings to predict in vivo efficacy. The growth of SW480 colon cancer cells, shown in vitro to be a user of βHB, was slowed to a greater extent when implanted in vivo to mice fed a ketogenic diet, when compared to H1299 lung cancer cells, which were not a user of βHB in vitro. Further investigations suggest that H1299 is a greater producer of lactate, which we hypothesize is being converted back to glucose in the liver via gluconeogenesis, causing the observed higher blood glucose and plasma insulin. This in turn, supports the growth of the H1299 cells in vivo, that could not be predicted by our in vitro assays. Taken together, we show that while it is not possible to predict the efficacy of a ketogenic diet using in vitro assays, it may be possible to identify which cancer cells may be impacted under low glucose conditions based on its propensity to produce lactate via glycolysis.

PLoS ONEVol. 21(11)
BC Cancer Agency (CA)
Lotte and John Hecht Memorial Foundation
Good health and well-being
Diet and metabolism studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon